Opioid Use, Pain, Acute
Conditions
Keywords
Postoperative pain, Opioid, Sustained-release opioid
Brief summary
The advantage of slow-release opioid allows for less fluctuation in drug (pain killer) levels in the blood and an extended period within the effective range for pain relief. The slow-release opioids have been preferred over the short-acting opioids because of the longer duration of action, which lessens the frequency and severity of end-of-dose pain. Herein, the investigators propose the use of low dose slow-release opioid formulation offers better pain control in the first 48 hours post-operatively in open abdominal urologic surgeries.
Detailed description
This will be a randomized, double-blind, controlled trial looking at all adult patients undergoing open abdominal urologic surgeries. After assessing the inclusion/exclusion criteria, the patients will be randomized into one of two groups: Group 1: Sustained-release (long-acting) opioid on a regular basis for 2 days with immediate-release (short-acting) opioid available on an 'as required' basis Group 2: Immediate-release (short-acting) opioid on an 'as required' basis only. All patients will have a general anesthetic at the discretion of the anesthesiologist in the operating room and intravenous opioid will be administered in accordance with the anesthesiologists' discretion. Pain score and analgesic consumption are the outcome measures.
Interventions
Sustained-release hydromorphone is a long-acting preparation opioid
Sponsors
Study design
Eligibility
Inclusion criteria
* All adult patients undergoing open abdominal urologic surgeries * ASA 1-3
Exclusion criteria
* Patient refusal * history of chronic pain * allergy to hydromorphone * cannot swallow tablets
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Mobilization | Time to mobilize postoperatively up to 5 days | Ability to walk from bed to chair |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Opioid consumption of hydromorphone | Postoperatively in recovery, 24 hours, 48 hours and 72 hours postoperatively | Consumption of hydromorphone |
| Pain score | postoperatively day 1, 2, 3 | Pain score using visual analogue scale 0-100 |
Countries
Canada